Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Recently Novo Nordisk announced the initiation of REDEFINE 4, a phase 3 trial comparing CagriSema 2.4 mg with Lillys Zepbound 15 mg evaluating weight loss after 72 weeks in 800 obese patients non-diabetic and is expected to be completed by October 2025 (NCT06131437)
You may decide to remain on your current Wegovy pen for longer than four weeks if you are satisfied with your weight loss progress, or if youre finding the side effects challenging to manage
Both require a physician's prescription, and both deliver the same active ingredient to support weight loss through appetite reduction and improved blood sugar control
Muscle tissue is the primary site of glucose uptake in the body
US$ 29.47
US$ 29.57
US$ 22.96
US$ 27.06
